ACR 2022 Tweet by sheila

Tweet
sheila @RHEUMarampa Nov 12, 2022
View on
Post hoc analysis from the SELECT-PsA 1 trial by Dr. @DrLauraCoates and team:
💊Pts on UPA showed greater improvement from BL in RAPID3 vs. ADA in all visits
💊Pts on UPA had better responses in all assessments vs. PBO
Reassuring data. #ACR22 @RheumNow ABST0192
Image from sheila’s tweet

Related Content

Video Education/ACR/EULAR

DERM on RheumNow PODCAST (September 2026)

Sep 30, 2026
The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, calcinosis, CTD skin disorders. dermatology drugs, biologics, and JAK inhibitors.Features Dr. Jack Cush, Editor at RheumNow.com.Show Notes:FDA Grants Priority Review…
Article JAK/TYK2

Are JAK Inhibitors Better at Pain Relief in RA?

MedPage Today Jan 21, 2026
Among rheumatoid arthritis (RA) patients responding to upadacitinib (Rinvoq) or adalimumab, those receiving the former had significantly less residual pain with treatment, according to a post-hoc analysis of phase III trial data.
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×